 The U.S. Department of Health and Human Services HHS has exercised its option to purchase an additional 10,000 doses of BioCryst Pharmaceuticals Incs NASDAQ: BCRX Rapivab peramivir injection The govt will pay approximately 7 million for the Antiviral influenza therapy. The Rapivab purchase will supply the Strategic National Stockpile. 